Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

An international research team led by Oxford University scientists, including Christina Dold, Sagida Bibi and Elizabeth Clutterbuck from the Oxford Vaccine Group, has developed a portable test for antibodies that fight the novel coronavirus that causes COVID-19.

The test, described in a paper published in Nature Communications, which spots the presence of virus-fighting antibodies rather than a coronavirus infection, can be adapted to work on blood from a finger prick – making it quick and easy to use. The research team, which includes scientists from Taiwan, India, Thailand and France, as well as UK university and NHS researchers, trialled the test on patients with COVID-19, but now hope to adapt it to identify those who have successfully generated antibodies after a vaccine, versus those who may need a booster.

The scientists also hope that the large-scale use of their tests might help researchers and policy-makers track levels of protective immunity in the community.

Detecting antibodies

Antibodies are large proteins that lock onto and help the body’s immune system fight off disease-causing organisms, such as the novel coronavirus that causes COVID-19. Both infection with the virus and vaccines can generate antibodies.

There are already several commercial tests, which can detect whether someone has antibodies against the novel coronavirus, but these tests are expensive and usually need a central laboratory to analyse them. This is especially a problem in low-income countries.

Study lead Professor Alain Townsend from the MRC Human Immunology Unit at Oxford University said: 'Our test is very cheap to produce, so we are using existing funding from charitable donations to offer 10 million tests for research purposes to countries that cannot support very high-tech solutions.'

The test relies on linking a part of the viral spike protein to the surface of red blood cells. When antibodies to the virus are present they create a clump of red blood cells. This clump is big enough to be seen by eye.

The test also does not require any special equipment or take a long time to show the results, and is accurate: “It correctly identifies coronavirus spike protein antibodies 90% of the time, with less than a 1% false positive rate.”

Professor Townsend said: “All we need to do is mix a low-cost reagent with a small blood sample, and the clumping of the red cells after one hour shows whether the blood sample contained antibodies against the novel coronavirus or not.”

The Townsend-Jeantet charitable trust, run by Professor Townsend, will fund the production of sufficient reagent for 10 million test wells by an Oxford company Absolute Antibody.

Professor Townsend said: “We are already distributing our test reagent to researchers who need them anywhere in the world, free of charge. So far, we supplied our tests to researchers in twenty-one different countries, with major studies using our antibody test in Norway, Colombia, Taiwan and Sri Lanka.”

The team have also developed new versions of the reagent that that can test for antibodies to the new variant viruses through a recent generous donation from a local donor.

For ease of use so that the tests can be carried out in a variety of locations, even in your own home. The researchers note that they can be adapted to work using blood from a finger prick sample. They now plan to use this very simple test in future trials to see if it can identify those who are protected against COVID-19 from those who may need a booster vaccination.

Professor Alison Simmons, Director of the MRC Human Immunology Unit at Oxford University, said: “This study and the research developments by the team are a very valuable asset to our toolbox in our fight against the novel coronavirus. With better ways of testing antibody levels and understanding immune defences of individuals and across populations, we increasingly take steps towards being able to protect more people globally and control spread of the virus.”

Similar stories

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19 Vaccinology

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.